ProLungdx was selected to present alongside some of the most promising life science companies at the BIO Investor Forum. "The BIO Investor Forum, now in its 15th year, is designed to help biotechnology companies find sources of capital. Attendees have opportunities to learn about the latest investment trends as well as showcase their company to qualified investors," said Theresa Brady of the BIO Investor Forum.
The EPN Scan is nearing completion of its pivotal work with 14 premier US cancer centers. These represent a consensus of thought leaders seeking to accelerate the assessment of lung cancer risk in pulmonology, radiology, and thoracic surgery. Concern has rapidly increased following this year's introduction and national reimbursement coverage of the low-dose CT chest screen for lung cancer. The screen has been shown to have a 96% false positive rate for cancer and highlights the need for immediate risk stratification of potential lung cancer. Leading medical experts universally agree that advances in lung cancer risk management present the largest opportunity to reduce cancer mortality.
Steven Eror, President and CEO of ProLungdx, will present on Wednesday, October 19 at 1:45pm. The BIO Investor Forum will take place on Oct. 18 and 19 at the Westin St. Francis Hotel in San Francisco, California.
ProLungdx's mission is to make a difference in time for lung cancer patients. ProLungdx is a US-based medical technology company that develops, manufactures and commercializes innovative solutions that may shorten the time to diagnosis, thereby expanding the therapeutic window for lung cancer patients. The EPN Scan™ is approved for sale in Europe. For more information, visit www.prolungdx.com.
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause ProLungdx's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that the EPN Scan will not perform as suggested by this press release or that the US FDA will permit ProLungdx to market the EPN Scan. Forward-looking statements in this press release speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.
Ryan Snow | +1-801-503-9231 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/prolungdx-unveils-its-epn-scan-at-the-bio-investor-forum-long-awaited-test-for-those-at-risk-of-lung-cancer-300344852.html